Netherlands-incorporated Mylan (Nasdaq: MYL) has received another boost in its aim to market a generic version of Teva Pharmaceutical Industries' (NYSE: TEVA) multiple sclerosis (MS) treatment Copaxone (glatiramer acetate) 40mg/mL.
The US Patent and Trademark Office (PTO) has ruled in favor of Mylan by invalidating another of the Israeli company’s patents for the big-selling drug.
This comes after the PTO's Patent Trial and Appeal Board (PTAB) last week found Teva's first two Copaxone patents unpatentable in Mylan's inter partes review challenge.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze